Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 y

Mark H. Einstein, Mira Baron, Myron J. Levin, Archana Chatterjee, Bradley Fox, Sofia Scholar, Jeffrey Rosen, Nahida Chakhtoura, Dorothée Meric, Francis J. Dessy, Sanjoy K. Datta, Dominique Descamps, Gary Dubin

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

In this observer-blind study (NCT00423046), women (N = 1,106), stratified by age (18-26, 27-35, 36-45 y), were randomized (1:1) to receive the HPV-16/18 vaccine (Cervarix® , GlaxoSmithKline Biologicals, Months 0, 1, 6) or the HPV-6/11/16/18 vaccine (Gardasil® Merck and Co., Inc., Months 0, 2, 6). Month 7 results were previously reported; we now report Month 24 results. In the according-to-protocol cohort for immunogenicity (seronegative and DNA-negative at baseline for HPV type analyzed), seropositivity rates of neutralizing antibodies (nAbs) [pseudovirion-based neutralization assay] were, across all age strata, 100% (HPV-16/18 vaccine) and 97.5-100% (HPV-6/11/16/18 vaccine) for HPV-16, and 99.0-100% (HPV-16/18 vaccine) and 72.3-84.4% (HPV-6/11/16/18 vaccine) for HPV-18. Corresponding geometric mean titers (GMTs) were 2.4-5.8-fold higher for HPV-16 and 7.7-9.4-fold higher for HPV-18 with the HPV-16/18 vaccine vs. the HPV-6/11/16/18 vaccine; HPV-16 and HPV-18 GMTs were significantly higher with the HPV-16/18 vaccine than the HPV-6/11/16/18 vaccine (p < 0.0001) in the total vaccinated cohort (received ≥1 vaccine dose, irrespective of baseline sero/DNA-status). Similar results were obtained using enzyme-linked immunosorbent assay (ELISA ). Positivity rates and GMTs of antigen-specific IgG antibodies in cervicovaginal secretions (ELISA ) were not significantly different between vaccines. At Month 24, CD4 + T-cell responses for HPV-16 and HPV-18 were higher with the HPV-16/18 vaccine; memory B-cell response was higher for HPV-18 with the HPV-16/18 vaccine and similar between vaccines for HPV-16. Both vaccines were generally well tolerated. Although an immunological correlate of protection has not been defined, differences in the magnitude of immune response between vaccines may represent determinants of duration of protection.

Original languageEnglish (US)
Pages (from-to)1343-1358
Number of pages16
JournalHuman Vaccines
Volume7
Issue number12
DOIs
StatePublished - Dec 2011

Fingerprint

Human papillomavirus 11
Human papillomavirus 6
Human papillomavirus 18
Human papillomavirus 16
Vaccines
Safety
Enzyme-Linked Immunosorbent Assay

Keywords

  • Cervarix®
  • Gardasil®
  • Human papillomavirus
  • Immunogenicity
  • Safety

ASJC Scopus subject areas

  • Immunology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine : Follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 y. / Einstein, Mark H.; Baron, Mira; Levin, Myron J.; Chatterjee, Archana; Fox, Bradley; Scholar, Sofia; Rosen, Jeffrey; Chakhtoura, Nahida; Meric, Dorothée; Dessy, Francis J.; Datta, Sanjoy K.; Descamps, Dominique; Dubin, Gary.

In: Human Vaccines, Vol. 7, No. 12, 12.2011, p. 1343-1358.

Research output: Contribution to journalArticle

Einstein, MH, Baron, M, Levin, MJ, Chatterjee, A, Fox, B, Scholar, S, Rosen, J, Chakhtoura, N, Meric, D, Dessy, FJ, Datta, SK, Descamps, D & Dubin, G 2011, 'Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 y', Human Vaccines, vol. 7, no. 12, pp. 1343-1358. https://doi.org/10.4161/hv.7.12.18281
Einstein, Mark H. ; Baron, Mira ; Levin, Myron J. ; Chatterjee, Archana ; Fox, Bradley ; Scholar, Sofia ; Rosen, Jeffrey ; Chakhtoura, Nahida ; Meric, Dorothée ; Dessy, Francis J. ; Datta, Sanjoy K. ; Descamps, Dominique ; Dubin, Gary. / Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine : Follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 y. In: Human Vaccines. 2011 ; Vol. 7, No. 12. pp. 1343-1358.
@article{dc9e7aaed91d409e8835ae7e51fd9173,
title = "Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 y",
abstract = "In this observer-blind study (NCT00423046), women (N = 1,106), stratified by age (18-26, 27-35, 36-45 y), were randomized (1:1) to receive the HPV-16/18 vaccine (Cervarix{\circledR} , GlaxoSmithKline Biologicals, Months 0, 1, 6) or the HPV-6/11/16/18 vaccine (Gardasil{\circledR} Merck and Co., Inc., Months 0, 2, 6). Month 7 results were previously reported; we now report Month 24 results. In the according-to-protocol cohort for immunogenicity (seronegative and DNA-negative at baseline for HPV type analyzed), seropositivity rates of neutralizing antibodies (nAbs) [pseudovirion-based neutralization assay] were, across all age strata, 100{\%} (HPV-16/18 vaccine) and 97.5-100{\%} (HPV-6/11/16/18 vaccine) for HPV-16, and 99.0-100{\%} (HPV-16/18 vaccine) and 72.3-84.4{\%} (HPV-6/11/16/18 vaccine) for HPV-18. Corresponding geometric mean titers (GMTs) were 2.4-5.8-fold higher for HPV-16 and 7.7-9.4-fold higher for HPV-18 with the HPV-16/18 vaccine vs. the HPV-6/11/16/18 vaccine; HPV-16 and HPV-18 GMTs were significantly higher with the HPV-16/18 vaccine than the HPV-6/11/16/18 vaccine (p < 0.0001) in the total vaccinated cohort (received ≥1 vaccine dose, irrespective of baseline sero/DNA-status). Similar results were obtained using enzyme-linked immunosorbent assay (ELISA ). Positivity rates and GMTs of antigen-specific IgG antibodies in cervicovaginal secretions (ELISA ) were not significantly different between vaccines. At Month 24, CD4 + T-cell responses for HPV-16 and HPV-18 were higher with the HPV-16/18 vaccine; memory B-cell response was higher for HPV-18 with the HPV-16/18 vaccine and similar between vaccines for HPV-16. Both vaccines were generally well tolerated. Although an immunological correlate of protection has not been defined, differences in the magnitude of immune response between vaccines may represent determinants of duration of protection.",
keywords = "Cervarix{\circledR}, Gardasil{\circledR}, Human papillomavirus, Immunogenicity, Safety",
author = "Einstein, {Mark H.} and Mira Baron and Levin, {Myron J.} and Archana Chatterjee and Bradley Fox and Sofia Scholar and Jeffrey Rosen and Nahida Chakhtoura and Doroth{\'e}e Meric and Dessy, {Francis J.} and Datta, {Sanjoy K.} and Dominique Descamps and Gary Dubin",
year = "2011",
month = "12",
doi = "10.4161/hv.7.12.18281",
language = "English (US)",
volume = "7",
pages = "1343--1358",
journal = "Human Vaccines",
issn = "1554-8600",
publisher = "Landes Bioscience",
number = "12",

}

TY - JOUR

T1 - Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

T2 - Follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 y

AU - Einstein, Mark H.

AU - Baron, Mira

AU - Levin, Myron J.

AU - Chatterjee, Archana

AU - Fox, Bradley

AU - Scholar, Sofia

AU - Rosen, Jeffrey

AU - Chakhtoura, Nahida

AU - Meric, Dorothée

AU - Dessy, Francis J.

AU - Datta, Sanjoy K.

AU - Descamps, Dominique

AU - Dubin, Gary

PY - 2011/12

Y1 - 2011/12

N2 - In this observer-blind study (NCT00423046), women (N = 1,106), stratified by age (18-26, 27-35, 36-45 y), were randomized (1:1) to receive the HPV-16/18 vaccine (Cervarix® , GlaxoSmithKline Biologicals, Months 0, 1, 6) or the HPV-6/11/16/18 vaccine (Gardasil® Merck and Co., Inc., Months 0, 2, 6). Month 7 results were previously reported; we now report Month 24 results. In the according-to-protocol cohort for immunogenicity (seronegative and DNA-negative at baseline for HPV type analyzed), seropositivity rates of neutralizing antibodies (nAbs) [pseudovirion-based neutralization assay] were, across all age strata, 100% (HPV-16/18 vaccine) and 97.5-100% (HPV-6/11/16/18 vaccine) for HPV-16, and 99.0-100% (HPV-16/18 vaccine) and 72.3-84.4% (HPV-6/11/16/18 vaccine) for HPV-18. Corresponding geometric mean titers (GMTs) were 2.4-5.8-fold higher for HPV-16 and 7.7-9.4-fold higher for HPV-18 with the HPV-16/18 vaccine vs. the HPV-6/11/16/18 vaccine; HPV-16 and HPV-18 GMTs were significantly higher with the HPV-16/18 vaccine than the HPV-6/11/16/18 vaccine (p < 0.0001) in the total vaccinated cohort (received ≥1 vaccine dose, irrespective of baseline sero/DNA-status). Similar results were obtained using enzyme-linked immunosorbent assay (ELISA ). Positivity rates and GMTs of antigen-specific IgG antibodies in cervicovaginal secretions (ELISA ) were not significantly different between vaccines. At Month 24, CD4 + T-cell responses for HPV-16 and HPV-18 were higher with the HPV-16/18 vaccine; memory B-cell response was higher for HPV-18 with the HPV-16/18 vaccine and similar between vaccines for HPV-16. Both vaccines were generally well tolerated. Although an immunological correlate of protection has not been defined, differences in the magnitude of immune response between vaccines may represent determinants of duration of protection.

AB - In this observer-blind study (NCT00423046), women (N = 1,106), stratified by age (18-26, 27-35, 36-45 y), were randomized (1:1) to receive the HPV-16/18 vaccine (Cervarix® , GlaxoSmithKline Biologicals, Months 0, 1, 6) or the HPV-6/11/16/18 vaccine (Gardasil® Merck and Co., Inc., Months 0, 2, 6). Month 7 results were previously reported; we now report Month 24 results. In the according-to-protocol cohort for immunogenicity (seronegative and DNA-negative at baseline for HPV type analyzed), seropositivity rates of neutralizing antibodies (nAbs) [pseudovirion-based neutralization assay] were, across all age strata, 100% (HPV-16/18 vaccine) and 97.5-100% (HPV-6/11/16/18 vaccine) for HPV-16, and 99.0-100% (HPV-16/18 vaccine) and 72.3-84.4% (HPV-6/11/16/18 vaccine) for HPV-18. Corresponding geometric mean titers (GMTs) were 2.4-5.8-fold higher for HPV-16 and 7.7-9.4-fold higher for HPV-18 with the HPV-16/18 vaccine vs. the HPV-6/11/16/18 vaccine; HPV-16 and HPV-18 GMTs were significantly higher with the HPV-16/18 vaccine than the HPV-6/11/16/18 vaccine (p < 0.0001) in the total vaccinated cohort (received ≥1 vaccine dose, irrespective of baseline sero/DNA-status). Similar results were obtained using enzyme-linked immunosorbent assay (ELISA ). Positivity rates and GMTs of antigen-specific IgG antibodies in cervicovaginal secretions (ELISA ) were not significantly different between vaccines. At Month 24, CD4 + T-cell responses for HPV-16 and HPV-18 were higher with the HPV-16/18 vaccine; memory B-cell response was higher for HPV-18 with the HPV-16/18 vaccine and similar between vaccines for HPV-16. Both vaccines were generally well tolerated. Although an immunological correlate of protection has not been defined, differences in the magnitude of immune response between vaccines may represent determinants of duration of protection.

KW - Cervarix®

KW - Gardasil®

KW - Human papillomavirus

KW - Immunogenicity

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84855181757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855181757&partnerID=8YFLogxK

U2 - 10.4161/hv.7.12.18281

DO - 10.4161/hv.7.12.18281

M3 - Article

C2 - 22048173

AN - SCOPUS:84855181757

VL - 7

SP - 1343

EP - 1358

JO - Human Vaccines

JF - Human Vaccines

SN - 1554-8600

IS - 12

ER -